(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
Craig W
CW
Lindsley
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000737:chemistry / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D015283:Citalopram / Q000008:administration & dosage / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000191:economics; D004311:Double-Blind Method; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006801:Humans; D008464:Mecamylamine / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015394:Molecular Structure; D015337:Multicenter Studies as Topic; D018733:Nicotinic Antagonists / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013237:Stereoisomerism
D000928:Antidepressive Agents; D015283:Citalopram; D008464:Mecamylamine; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D017367:Selective Serotonin Reuptake Inhibitors; C403531:nicotinic receptor alpha4beta2